pelacarsen Lp(a)
Selected indexed studies
- Pelacarsen: Mechanism of action and Lp(a)-lowering effect. (J Clin Lipidol, 2025) [PMID:40781022]
- LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. (Annu Rev Pharmacol Toxicol, 2024) [PMID:37506332]
- Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). (Am Heart J, 2025) [PMID:40185318]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. (2024) pubmed
- Lp(a): A Rapidly Evolving Therapeutic Landscape. (2024) pubmed
- Lipoprotein a - Lp(a). (2024) pubmed
- Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. (2022) pubmed
- Therapeutic Potential of Lipoprotein(a) Inhibitors. (2024) pubmed
- Pelacarsen: Mechanism of action and Lp(a)-lowering effect. (2025) pubmed
- Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). (2025) pubmed
- Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. (2022) pubmed
- Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects. (2023) pubmed
- Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. (2026) pubmed